FT : Russian tycoon Mikhail Fridman warns rapid switch from gas is ‘irresponsibl

Russian tycoon Mikhail Fridman warns rapid switch from gas is ‘irresponsible’
Billionaire to invest more in renewable energy but says transition will be ‘very challenging process’

Russian billionaire Mikhail Fridman has warned that moving too fast from gas to renewable energy would be “dangerous and irresponsible”, arguing that the recent energy crisis can be partly blamed on the industry being undervalued.

Fridman said he would invest more in alternative energy to reduce the carbon impact of his oil and gas empire.

But he cautioned against switching off gas supplies too quickly, saying the recent price surge reflected a lack of investment by companies given the “huge public pressure for decarbonisation”, and the signal this gave to investors and banks “to cut the relationship with oil and gas business”. 

He expected gas would be important for the energy mix for “dozens of years”.

“Transition is a very complicated and very challenging process,” he told the Financial Times in an interview at his Mayfair headquarters. “For the time being, we don’t have any viable alternative to living without gas.”

Fridman is one of Russia’s richest businessmen but spends half his time in the UK. LetterOne, his holding group, has more than $10bn to invest, and will announce its latest deal with a UK-based recycling business next week.

The company’s pre-tax profit for 2021 is expected to exceed $5bn.

Fridman has extensive holdings in Russia through Alfa Group, which he co-founded in 1991, but set up LetterOne with his partners in London in 2013 using $14bn raised from the sale of a stake in oil firm TNK-BP to Rosneft.

LetterOne’s largest business is its energy division, which is chaired by former BP boss John Browne, but the investment group has a sprawling portfolio spanning telecoms, energy and retail businesses.

Fridman’s long-term strategy is putting his company at odds with other investors in the sector.

He signalled a forthcoming wrangle over the future of Wintershall Dea, Europe’s largest independent gas and oil company, in which LetterOne owns a third, alongside the majority shareholder BASF.

Fridman pointed to the pressure the German company had faced from investors and activists over its stake in the gas producer, and said there was “a distinction in approach” between LetterOne and BASF. BASF wants to sell its stake in the 127-year-old German business through an IPO, but LetterOne wants “to build a long-term strategy”.

“For us, it’s a [long-term] mission to hold the business in the right direction. For BASF it’s a bit different,” he added.

LetterOne is unlikely to sell out in any IPO at this point, and will not block the process, but could support a sale of part of the company to a private equity buyer.

Fridman wants to support the company’s hugely profitable gas business alongside investing in renewables businesses and technology that “diminishes the negative environmental damage”.

He said: “Let’s try to combine these two approaches.”

In the UK, LetterOne is investing up to £1bn in fibre broadband in a regional infrastructure company called Upp, and in the healthcare sector it owns retailer Holland & Barrett, which Fridman said would have a new business model orientated towards services alongside products.

He said the general environment in the UK for oligarchs had “deteriorated because of the stand-off between Russia and the west”, but added that “on a personal level, it’s become a bit more friendly, because people made a distinction between the general Russian oligarchs label and us personally”. 

Even so, he said there was a “kind of competitive disadvantage as a Russian” that required “additional efforts to convince people that we are doing things right”. 

The UK government, he added, had “a lot of information to make a distinction between good people and bad people . . . It will be important to find a way to make a distinction between politics, and those who like me want to become a normal business citizen . . . We try to be as transparent as possible.”

The billionaire said he did not intend to give his five children any of his wealth, describing it as “dangerous” to inherit so much money and important that they made their own way.

Unlike other Russian oligarchs, he is not a “glamorous person” with the “talent” to spend money. “I don’t have yachts. I don’t have planes. I have a house in London. I have a house in Moscow.”

FT : Bouygues prevails in auction for Engie’s energy services business

Bouygues prevails in auction for Engie’s energy services business
Fraught bidding for a significant French employer prompted allegations that foreign investors were getting short shrift

French state-backed group Engie has selected a €7.1bn bid from conglomerate Bouygues to buy its energy services division, after a fraught auction that took on a political edge six months ahead of presidential elections.

Bouygues, which is controlled by billionaire industrialist Martin Bouygues and his family, beat US private equity firm Bain and France’s Eiffage, a civil engineering company.

The battle for Equans, which undertakes energy efficiency projects and facilities management for corporate clients, had raised hackles among rival bidders over who the government would back and whether foreign suitors would stand a chance.

With a near 24 per cent stake in utility Engie, giving it three out of 14 board seats, the French state had a significant role in picking the winner. Equans’ status as a large employer, with more than a third of its 74,000 workers in France, added to the sensitivity of the sale.

Seven bidders were originally in the running, including several international private equity firms, some of which alleged that foreign investors were getting short shrift. They questioned whether the state was favouring Bouygues given that the group has extensive government contracts and Martin Bouygues has been a longtime ally of the president, Emmanuel Macron.

Engie said on Saturday that it would enter exclusive negotiations with Bouygues, and that the deal was expected to complete in the second half of 2022.

Engie chief executive Catherine MacGregor told the Financial Times that Bouygues had put in the highest bid. She said its proposal was a good fit culturally for Equans and “had really stood among all offers and made it almost an easy decision”.

Asked about backbiting surround the deal, MacGregor said that the sale had sparked a “strong competitive spirit” among bidders but that the process had been rigorous.

“It allows us to simplify the group in order to grow our core businesses, notably renewable energy,” MacGregor said of the disposal.

Engie, which has been trying to refocus its sprawling structure, also sold a stake in waste and water management Suez last year as it raises funds for investments.

The takeover of Equans is Bouygues’ biggest ever acquisition. Once the deal is finalised, Equans will become its largest division, adding roughly €12bn in annual revenue and representing just under a quarter of the enlarged group.

Bouygues is betting it can benefit from a wave of post-Covid infrastructure spending plans from the US to Europe.

It pledged not to fire any workers in Europe for five years after the deal closes, and promised to create an additional 10,000 jobs in that time.

Equans, a newly created division within Engie, groups together myriad businesses that install refrigeration and heating systems or specialise in electrifying transport networks. The business is labour intensive and has been hit by shortages and hiring difficulties.

9to5 : How Apple Card+ could rival other premium cards with exclusive perks and



One of Apple’s best services is Apple Card. Sure, it might just be another credit card that happens to have a really great app in Wallet, but Apple Card could be much more than that. Currently, Apple Card offers excellent customer support, powerful security features, and one of the best physical cards you can get your hands on. Folks like Mark Gurman over at Bloomberg have been wondering, though, what could be next for Apple Card? We’ve been wondering the same thing, and here’s a dive into our ideas.




The first thing we’d like to see for an “Apple Card+” is an improved, and frankly, more badass physical card. It starts with a new dark finish that you could call space gray if you wanted to. Apple tends to like to make its higher-end products in darker colors so here’s a golden opportunity to show off. The current Apple Card is missing one big feature, and that’s tap to pay. You are required to swipe or insert your chip with the current card, so it would be great to see Apple add Apple Pay to the next one. I love being able to tap my bank cards to terminals just like how I tap my iPhone or Apple Watch. It doesn’t make sense for the Apple Card to be missing such a simple feature of modern credit cards.


Next up are Apple retail store perks. Currently, Apple offers 3% cash back on Apple products bought through the Apple store. I think an Apple Card+ should offer 5% cash back. After all, anyone with an Apple Card+ is more than likely an Apple fan. I’d also like to see them raise the general cash back percentage to a standard 3%.


Apple could also offer customers complimentary expedited shipping on orders, an extra 5% when you trade in a device, and an extra year of Apple Care when it’s purchased with an Apple Card+. In terms of customer support, Apple could offer customers with an Apple Card+ same-day Genius Bar reservations. That’s one of the biggest gripes about the current Apple Store situation – it’s nearly impossible to get into an Apple Store immediately for help with a problem. And with lots of customers shopping with in-store pick up, we’d also like to see Apple offer priority pick up times for Apple Card+ customers.




A fairly simple and hopefully obvious addition is an extended return window for products. Apple currently offers two weeks to return a purchase, but with Apple Card+, Apple could offer a full 30 days. The current window is just too short for most customers to get a good feel for some products.


One really fun idea that we have is exclusive iOS app offers. Apple could offer Apple Card+ customers special perks when it comes to things like in-app purchases, paid apps, and specialty physical orders within apps. Apple is currently offering special deals to Apple Card users who use apps like Panera, so this isn’t much of a stretch.


Lastly, Apple Card+ would require an Apple One subscription and should probably require users to meet a certain credit limit. It wouldn’t make any sense for Apple to offer Apple Card+ and all of its perks to everyone out of the gate.


So those are our ideas for Apple Card+. What ideas might you have for an improved Apple Card experience? Let us know in the comments below.

WWD : Kim Jones and Travis Scott Talk Trust, Breaking Rules and Paying It Forwar

Kim Jones and Travis Scott Talk Trust, Breaking Rules and Paying It Forward
At the WWD Apparel & Retail CEO Summit, the Men’s Wear Designers of the Year discussed their groundbreaking collaboration on the Dior spring men's collection.

Ever since his game-changing collaboration with Supreme as head men’s wear designer at Louis Vuitton, Kim Jones has been deft at setting creative partnerships that generate media buzz and fuel his creative inspiration season after season.

Since taking over as men’s artistic director at Dior in 2018, he’s worked with artists including Kaws, Daniel Arsham and Kenny Scharf on collections that have turbocharged the business. But his latest collaboration was yet another era-defining moment, as Travis Scott became the first musician to create a full collection with Dior.

The collaboration between Jones and Scott — and the influence it generated — earned the two men the WWD Honor for Men’s Wear Designers of the Year. In an online interview with Alex Badia, style director of WWD, at the summit, they revealed the challenges of working together in the midst of a global pandemic, and how mutual trust was key to the process.

“Man, it was actually crazy. I was in Cabo, I was working on my album,” said Scott, referring to “Utopia,” the eagerly awaited follow-up to his hit album “Astroworld.” When he got the call from Jones, he thought it was just a friendly check-in.

“And then when he was explaining to me a little bit more, I’m like, ‘Oh yeah, OK, we’re gonna make, like, you know, a couple of things.’ And then we linked up, I was like, ‘Oh, wow, this is crazy.’ You know, all these different ideas start fleshing out, so it was amazing to see where it started and how it grew to be where it went,” he added.

For Jones, collaborations were a way to stay in touch with friends during months of pandemic-imposed solitude at home in London.

“We did this collection in a very challenging time of lockdown, and I think we did such a good job on it,” said the designer, noting that distance is not a bad thing, provided the creative channels stay open. “It’s giving people freedom to do what they want, and that is really what it’s about. And that’s why you work with people — you can only do a collaboration with someone you trust.”

A case in point: the soundtrack to the show, which included a new track called “Lost Forever,” cowritten by Scott with James Blake and Westside Gunn. “Travis went off and did the music at the very last minute, and that, for me, is quite a weird thing, but the music was perfect,” said Jones, who is known for his meticulous advance planning.

“It was a good challenge of being able to try to create at a higher level, and not all the time be next to each other,” Scott concurred, noting that he was in the U.S., Jones and his team in London, and the prototypes in Paris.

“We’re making it work and everyone’s shifting around. It just made me appreciate the idea of being able to bounce ideas back and forth with someone that you can trust to understand what you’re trying to do. I think that was, like, literally one of the main key components that, you know, we kind of like understood each other, so it was a very good back and forth,” he said.

The two first connected at that Supreme show at Vuitton in 2017. “We just hung out from there,” Scott said. “It’s like a friendship — whether it’s music, clothes or just life in itself. And then from there, we just put some ideas together and kept it going.”

The Dior collection is the latest in Scott’s winning streak of partnerships with companies as diverse as Nike, Dover Street Market, Playstation, Epic Games and Byredo, prompting Forbes magazine to dub him “corporate America’s brand whisperer.” His collaboration with McDonald’s last year resulted in meat shortages and helped to drive up the fast-food giant’s shares.

A Grammy-nominated artist, songwriter, producer, businessman and designer, the rapper has also been lauded for his innovative music marketing strategies, such as bundling concert tickets, merchandise and a new album, and staging a virtual concert within Epic’s wildly successful Fortnite game.

“He looks at a genre in a different way, the way that it’s not just music: it’s fashion, it’s flipping around things, and so for me, he’s always inspiring,” Jones said. “I like sharing the spotlight with someone, especially like Travis who totally deserves it. It’s nice to see Travis excel at everything he does. I think it’s amazing.”

Last year, Scott became the unofficial ambassador of the Air Dior capsule line and its hugely popular Air Jordan 1 OG Dior sneakers. He has something of a Midas touch when it comes to footwear: In 2020, sneakers Scott codesigned sold on average for 370 percent more than their launch price on online resale platform StockX.

Dior hopes to have another hit on its hands with the skate-inspired B713 sneakers it showed with the spring men’s collection, which was named after Scott’s creative collective Cactus Jack. But what both men agreed on very quickly was not a streetwear vibe, but the tailored look that is at the core of the line: a narrow Oblique jacket paired with flared pants.

“I was just looking with someone in my studio at the way Travis dresses, because we’d made some things for him, for the Met [Gala in 2019]. And I just thought it would be nice to see it as a whole collection. That’s really how we got the conversation started,” explained Jones, adding there were a few surprises along the way.

“I think one of the favorite things was the Saddle bag that he created, with the stirrup handle that I would never have thought up,” he said.

Scott also took liberties with the Dior Oblique logo, twisting it to spell out the word “Jack.” It turns out Bernard Arnault, head of Dior’s parent company LVMH Moët Hennessy Louis Vuitton, personally OK’d the irreverent take on one of his most valuable pieces of intellectual property. “I was surprised that got through the net, but everyone loved it,” Jones remarked.

Meanwhile, watching the way a high-end fashion house operates has fed into Scott’s music-making routine.

“It’s interesting to see the workflow and the process of it. Every piece is very important and the level of detail is very serious, you know what I’m saying? And the same way for music, which is cool. Being able to see both avenues is kind of interesting, and definitely inspired me even just for my album now, to try new things, a different style of workflow, a different style of creating music — just being in a whole other mind-set,” he noted.

The line also contained a charitable component. As part of the collaboration, Dior will auction off four white shirts hand-painted by artist George Condo to benefit the fashion program created in partnership between Scott’s Cactus Jack Foundation and The New School’s Parsons School of Design.

“We’ve all been blessed enough to get where we’re at,” Scott said. “Anything we’re trying to do, I think it’s not about money and s–t. I think it’s just more also about the inspiration and trying to get somebody inspired to wake up, to be able to put out the same good product.”

Jones also has an eye on posterity. The show’s set, a psychedelic extravaganza featuring oversize blooms inspired by founder Christian Dior’s garden, and cacti symbolizing Scott’s home state of Texas, was informed by a show that former Dior artistic director John Galliano put on in 2005 to commemorate the 100th anniversary of Dior’s birth.

“I like the idea for people to look at it in 50 years when it’s in an exhibition about Dior, or about fashion, or about music. That’s the thing that interests me,” Jones said.

Both men agreed that the show represented a creative high they would need a little time to digest. Scott had the realization when he took his bow with Jones at the end of the show, with the elation of an athlete who’s just broken a world record.

“You go from moments of being outside, like trying to get a peek inside to see what’s going down in the shows, and now you’re inside, and then being able to be part of it,” he recalled. “Man, it was just so surreal. It all hit me right there. It was dope that, man, we actually got to this point.”

Now he’s focusing on his “Astroworld” festival, due to take place in Houston on Friday and Saturday. “That’s my number-one ambition right now, you know? I’m so happy [about] what we did, and now I’m so happy to just get to the next level, and music and shows and performances,” he said.

Likewise, Jones plans to take a little break before lining up another major collaboration. “I think it was pretty epic, so I don’t want to emulate it. I’ve got other things to do,” he said, hinting at yet another twist with his next collection.

FT : The pandemic boosts business for a top New York divorce lawyer

The pandemic boosts business for a top New York divorce lawyer
It’s boom times for Robert Stephan Cohen, who counts Melinda French Gates and John Paulson’s wife among his clients

Robert Stephan Cohen was already having a banner year as one of New York’s top divorce lawyers.

He represented Melinda French Gates in her split from Bill Gates, one of the planet’s wealthiest people. He was also retained by the wife of John Paulson, the hedge fund manager who made $20bn betting against the housing market before the 2008 financial crisis.

Then came Labor Day. The American holiday in early September marks the traditional end of summer. Many New Yorkers had anticipated this year’s holiday as a time to end their pandemic-induced isolation — and, apparently, also their marriages. Cohen has taken on three or four billion-dollar break-ups since then.

“I found that Labor Day was a signal to people who were getting out of seclusion in East Hampton or Mexico or wherever their second houses were,” said Cohen. “It was sort of a turning point for a lot of married couples, and I think they decided then to pull the plug.”

Now 82, Cohen has for decades proven singularly skilful at helping wealthy New Yorkers pull that plug. He has represented not one but two ex-wives of Donald Trump — Ivana Trump and Marla Maples — as well as former New York City Mayor Michael Bloomberg, shipping heiress Athina Onassis and the actor James Gandolfini, among other boldfaced names.

It is surprising, then, that Cohen never much wanted to be a divorce lawyer. “I backed into this,” he confessed. “If anybody had said I was a divorce lawyer, I would have been very unhappy because I didn’t think that was like a good thing to do.”

It started with a phone call thirty-odd years ago, when Cohen was a litigator with a growing reputation. One of New York City’s most august corporate lawyers had a client, Henry Kravis, who was being sued by his ex-wife over their divorce settlement. His firm, Simpson Thacher, did not want to involve itself in such matters, the lawyer explained. Could Cohen help?

He obliged, and managed to have the suit dismissed. The Wall Street Journal wrote of his exploits. “And my phone started to ring and the cases started to come in,” Cohen said.

While he has been called a “pit bull”, a “Doberman” and “your worst nightmare,” among other descriptors of extreme litigious ferocity, Cohen was easy-going and genial on a recent afternoon when welcoming a visitor to his Manhattan office. At this point in his career, it seems, the lion need only occasionally roar.

“I can do the tough stuff if I need to,” he assured.

Some of that toughness comes from a “lousy” childhood Cohen endured in a one-bedroom apartment on the border of Bensonhurst and Coney Island. His mother was chronically unhappy that her husband drove a taxi. She died at 37. Cohen’s father struggled and his sister, Ellen, was taken in by relatives. He graduated from high school early and then worked his way through Alfred University and Fordham law school, earning his degree in 1962.

“There are so many of us that came from the bowels of Brooklyn, in lower middle class families,” Cohen reflected.

During his army service Cohen spent much of his time at Fort Dix in New Jersey waiting for the pay phone so he could call the office of Roy Cohn, the notorious former chief counsel to Senator Joseph McCarthy’s anti-communist investigation committee — and the man who would later take a young Donald Trump under his raptor’s wing.

Cohen did not necessarily agree with his politics, he said, but he revered Cohn’s skills as a litigator. Eventually Cohn granted him an interview, and then a job. “That was really the first door that was opened for me,” Cohen said of his introduction to a gilded world of doorman buildings and chauffeur-driven cars.

The fearsome Cohn also honed a relentlessness bordering on lunatic, berating the young lawyer one evening after he informed him that he could not find a legal solution to a particular client problem.

“He started to scream at me. He said, ‘do you think clients come in here and tell us that we can’t do something? There’s got to be a way to do it,’” Cohen recalled. “He said, ‘do you see it’s dark out? I can tell you it’s daytime and I’ll prove it’s daytime.’”

Cohen became a partner, then left to start his own firm. “He had a host of failings, personal failings,” he said of Cohn, who was later disbarred.

Meanwhile, the divorce landscape was changing. It was becoming easier to obtain a divorce in states that had long required proof of serious fault, usually adultery. (Hence the unseemly divorce lawyer reputation as the snoop hiding in the motel bushes with a Polaroid camera). 

Then in 1980 New York mandated an equitable distribution of marital assets. Business boomed, and it has only grown as the rich have grown richer. Ivana Trump’s reported $14m settlement in 1991, for example, now seems like a rounding error in a Gates estate that includes a $55bn philanthropic foundation or an Onassis split that involved litigation in Belgium, Monaco and Brazil.

“It’s a big business. It requires people around who understand tax, who understand securities, and who understand how to value all of these various assets,” said Cohen. His firm, Cohen Clair Lans Greifer Thorpe & Rottenstriech, has three attorneys who are certified public accountants, as well as a network of outside specialists to help value exotic assets. It is only a matter of time, Cohen predicted, before he hires a cryptocurrency adviser.

For all the financial sophistication, divorce remains a people business — a lesson Cohen imparts to law students at the University of Pennsylvania where he has taught a class, Anatomy of a Divorce, for the last 17 years. “You have to be a quasi-psychologist or psychiatrist or mental health professional,” he said. “Remember, we’re dealing with people at probably the most difficult time of their lives.”

Cohen, who suffered two of his own divorces, has been married to Stephanie Stiefel, a managing director at Neuberger Berman, for 23 years. (He wears a Cartier trinity band with three interlaced strands). If one can avoid divorce, he strongly advises it. He even wrote a book in 2002, Reconcilable Differences, which promises seven keys to preserving a marriage.

“I’ve said this a hundred times: If people continue to be intimate, that’s often an important point for me in saying there may be something there left to save,” he said, adding: “It’s a tough business.”

>>> US Close Dow +0.56% S&P +0.37% Nasdaq +0.20% Russell +1.44%

Closing Stock Market Summary

Each of the major indices set intraday and closing record highs on Friday, supported by a stronger-than-expected October employment report, encouraging COVID-19 antiviral news from Pfizer (PFE 48.62, +4.77, +10.9%), pleasing earnings news, and another retreat in long-term interest rates.  

The market, however, closed off session highs. The S&P 500 (+0.4%), Nasdaq Composite (+0.2%), and Dow Jones Industrial Average (+0.6%) rose between 0.2-0.6% after being up 0.7-1.0% early in the session. The Russell 2000 outperformed with a 1.4% gain. 

Ten of the 11 S&P 500 sectors contributed to the advance. The energy (+1.4%) and industrials (+1.0%) sectors finished atop the standings with gains of at least 1.0%, while the health care sector (-1.0%) fell 1%, ironically due to the success of Pfizer. 

Prior to the open, Pfizer announced its COVID-19 oral antiviral reduced the risk of hospitalization or death by 89% in interim data. The news undercut shares of Merck (MRK 81.61, -8.93, -9.9%), which has a competing treatment, and shares of other vaccine makers like Moderna (MRNA 236.99, -47.03, -16.6%). MRK fell 10%, and MRNA fell 17%.  

As for the jobs data, nonfarm payrolls increased by 531,000 (Briefing.com consensus 400,000), the unemployment rate improved to 4.6% (Briefing.com consensus 4.7%) from 4.8% in September, and average hourly earnings increased 0.4% m/m (Briefing.com consensus 0.4%).

Despite the wage inflation, the 10-yr yield fell seven basis points to 1.45% in a move that signaled easing inflation concerns. The 2-yr yield decreased two basis points to 0.39%. The U.S. Dollar Index decreased 0.2% to 94.20.

This retracement in long-term rates was a supportive factor for the growth stocks for valuation reasons, although the value stocks outperformed today. The Russell 1000 Growth Index increased 0.2%. The Russell 1000 Value Index increased 0.5%.  

In addition to the Pfizer and jobs news, travel-related stocks in particular keyed off earnings results and/or guidance from Airbnb (ABNB 201.62, +23.17, +13.0%), Uber (UBER 47.19, +1.92, +4.2%), and Expedia (EXPE 182.17, +24.62, +15.6%). Airbnb spoke positively about travel, saying it expects strong demand to extend well into 2022.

The U.S. Global Jets ETF (JETS 24.63, +1.48, +6.4%) jumped 6.4%, undeterred by the 3% rebound in oil prices ($81.25, +2.48, +3.2%). 

Reviewing Friday's economic data:

  • Nonfarm and nonfarm private payroll growth in October were much stronger than expected and there was a further boost in nice upward revisions for prior months. At the same time, though, this report brought additional wage inflation, as average hourly earnings increased 4.9% year-over-year, versus 4.6% in September.
    • October nonfarm payrolls increased by 531,000 ( consensus 400,000). The 3-month average for total nonfarm payrolls decreased to 442,000 from 629,000 in September. September nonfarm payrolls revised to 312,000 from 194,000. August nonfarm payrolls revised to 483,000 from 366,000.
    • October private sector payrolls increased by 604,000 ( consensus 390,000). September private sector payrolls revised to 365,000 from 317,000. August private sector payrolls revised to 504,000 from 332,000.
    • October unemployment rate was 4.6% ( consensus 4.7%), versus 4.8% in September. Persons unemployed for 27 weeks or more accounted for 31.6% of the unemployed versus 34.5% in September. The U6 unemployment rate, which accounts for unemployed and underemployed workers, was 8.3%, versus 8.5% in September.
    • October average hourly earnings increased 0.4% (consensus 0.4%) versus a 0.6% increase in September. Over the last 12 months, average hourly earnings have risen 4.9%, versus 4.6% for the 12 months ending in September.
    • The average workweek in October was 34.7 hours ( consensus 34.8), versus 34.8 hours in September. Manufacturing workweek dipped 0.1 hours to 40.3 hours. Factory overtime dipped 0.1 hours to 3.2 hours.
      • The key takeaway from the employment report is the broad-based pickup in hiring activity across the private sector, as that will be interpreted as being a byproduct of dissipating Delta issues and employers seeing a favorable demand backdrop.
  • Consumer credit increased by $29.9 bln in September (consensus $17.0 bln) after increasing a revised $13.8 bln (from $14.4 bln) in August.
    • The key takeaway from the report is that consumer credit expanded for the eighth consecutive month, reflecting continued demand for goods and services.

There is no economic data of note scheduled for Monday. 

  • S&P 500 +25.1% YTD
  • Nasdaq Composite +23.9% YTD
  • Russell 2000 +23.4% YTD
  • Dow Jones Industrial Average +18.7% YTD

Barrons : Cryptos, NFTs, and Meme Stocks Are a Bubble. How to Dabble Safely.

Cryptos, NFTs, and Meme Stocks Are a Bubble. How to Dabble Safely.

Two days after Halloween, there were more costumes than usual in New York’s Times Square. Outside Jimmy Buffett’s Margaritaville restaurant, one man wore a mirrored face shield and knit beanie to resemble a CryptoPunk pixelated character. A vehicle transformed to look like a cockroach made from junk played a slow-speed rap about “stacks of cash” to market a digital art gallery. A cowboy crooner in underpants, himself as familiar as a pretzel stand to regular passersby, had been commissioned by a man and woman in matching onesies to sing about their holographic worm.

This was NFT.NYC, a conference promoting nonfungible tokens, which signify ownership of digital assets and can be flipped by profit-seekers. The zaniness of the attendees felt strained, but that of their virtual source material can hardly be overstated. Finance the world over is weirder now than it has ever been. A decade of near-zero interest rates has fueled a bubble of bubbles across assets real and virtual. But not everything is overpriced, and savers needn’t despair or pile into fun-house speculations.

Step back for a moment from individual reports of wild price gains for odd things, and take in the scope of it all. Just this year, NFT auctions have ended with $11.8 million paid for a CryptoPunk, $24.4 million for a collection of cartoon apes, and $69 million for a large assortment of drawings from a digital artist known as Beeple. These are not framed, one-of-a-kind pieces, but rather tokens proclaiming ownership of digital images that are copied freely across the internet.

That is nothing compared with cryptocurrency, an asset class younger than the iPhone. It is closing in on $3 trillion in market value, equal to about a quarter of the world’s mined gold, or the money supply of the United Kingdom. Dogecoin, a dog-themed, unlimited-supply parody crypto, is valued at $35 billion. It was eclipsed by Shiba Inu, a dog-themed parody of Dogecoin, which was worth $40 billion this past week—until it tumbled 20% on Thursday. In comparison, Hershey (ticker: HSY), the 127-year-old chocolate maker with operations in 85 countries, has a market value of $36 billion.

In meme stocks, GameStop (GME) and AMC Entertainment Holdings (AMC) at different points this year were up more than 20-fold. In special-purpose acquisition companies, or SPACs, Digital World Acquisition (DWAC) rose 15-fold after announcing that it would merge with Trump Media & Technology, whose best-known work is a slide deck of vague intentions to compete with Twitter , Facebook , Amazon . com, Apple , Walt Disney , and Netflix .

What can compare with all of this? Not Dutch tulips selling for as much as houses in the 17th century. That was a cosmopolitan folly, not, as was misreported many years later, a ruinous mania, as University of Southern California historian Anne Goldgar has shown. The South Sea bubble comes a bit closer, but it featured a stock that gained tenfold in 1720 and set off a rush of dubious new offerings, which is nothing that the trend-chasers on Reddit haven’t seen.

Dot-com stocks in the late 1990s? That was a frenzy, sure, but it was directionally correct, if a couple of decades early, before some of the best companies had blossomed. Japan in the 1980s? America’s Roaring ’20s? OK, those were doozies, and the economic aftermath was profound. But judging solely on weirdness, it’s unclear that credit-driven run-ups in stocks and real estate beat today’s run on virtual smiley faces, ironic stocks, and funny money.

This isn’t a valuation screed—not solely, at least. The world doesn’t need another asset-allocation traditionalist carrying on about Bitcoin not having cash flows. This is a hopeful note for ordinary savers and investors who no longer recognize their surroundings—who see abstract things selling for startling prices and wonder, on one hand, whether that’s dangerous for stocks, bonds, and traditional money, and, on the other, whether it’s too late to grab a stake in some new, fun, potential moon rocket.

Crypto assets don’t seem for now to present the sort of systemic risk that took down banks, or threatened to, during past crashes. “We could have another 1929 event, but the question is, who is it going to affect?” says Amy Lynch, a former financial regulator and founder of Frontline Compliance, which advises money managers. “As long as the major financial players are actually not offering their own crypto exchanges and cryptocurrency trading platforms, then we are quote-unquote safe from the systemic risk.” To Lynch’s point, a fast-gaining cryptocurrency themed after the Netflix series Squid Game collapsed to zero this past week in an apparent swindle. Only its unlucky holders were harmed.

Last month, Mastercard (MA) said that it would make it easier for merchants and banks to offer crypto services. But it will do so at arm’s length. Newly listed Bakkt Holdings (BKKT) will handle the plumbing.

Strategists who disagree sharply on crypto can nonetheless agree that stocks still make sense. David Kelly, chief global strategist for J.P. Morgan Asset Management , calls crypto a “cult masquerading as a currency,” and attributes its gains and other rampant asset inflation to the world’s central banks. “They’ve no business keeping long-term interest rates this low for this long,” he says. But he’s not altogether put off by stocks at current valuations.

Kelly says the top 10 stocks in the S&P 500 index trade at about 30 times forward earnings estimates, which is “too high,” but that the rest of the index trades at 20 times, “and that’s OK given where interest rates are.” And he reckons that shares in the rest of the world are 30% cheaper than those in the U.S.


Liz Young, head of investment strategy at SoFi Technologies (SOFI), a provider of smartphone-centric financial services, including crypto trading through a partnership with Coinbase Global (COIN), says that stocks should always be part of a long-term growth portfolio. Bonds no longer offer enough downside protection to offset stock risk, so investors should consider adding alternatives, and that can include crypto, she says.

With 8,800 cryptocurrencies to choose among, she views a shakeout as possible. “You don’t really know that you’re in a bubble until after it bursts, right?” she says. “So, then we look back at it and say, ‘Oh, 8,800 coins was an indication, or this many SPACs and NFTs.’ ” But Young says she expects crypto to endure as an asset class.

Crypto’s ever-evolving technology is easier to make sense of than its pricing. Bitcoin was conceived as a store of value and payment system existing outside the purview of central banks, with limited supply. Ethereum, the No. 2 crypto, is these things, plus more of a platform for new products, like NFTs. Both are viewed by critics as restrictive and slow for everyday transactions, and it takes shocking amounts of electricity to create new coins.

Two other top-10 cryptos, Polkadot and Cardano, were created by Ethereum co-founders, and are designed to address these shortcomings. Polkadot founder Gavin Wood tells Barron’s that his ambition is to create a foundational technology for the world’s financial system. Jeff Pollack, chief financial officer at IOHK, the company behind Cardano, says he can envision poor countries that lack a robust banking infrastructure adopting decentralized finance to level the field.

Neither can fully explain what makes Polkadot, up 500% this year, worth $60 billion, or Cardano, up 1,000%, worth $68 billion, but that is a question for buyers, not builders. Both seem less than thrilled by the run-up in parody coins distracting from their work. “I do get kind of exasperated,” says Wood. Pollack says, “I don’t like the projects that delegitimize the legitimate projects.”

For nonfungible tokens, as with crypto, it’s unclear how potential usefulness relates to pricing. The technology could provide artists with new ways to make money from their work, and power trading in unique, virtual objects within videogames or other online worlds. Hot Wheels is launching NFT Garage, packs of virtual cars with random rareness that can be sold for crypto or cash. Dolce & Gabbana recently auctioned a nine-piece collection of garments and crowns intended for museum display, with corresponding NFTs—a “way for the metaverse and the universe to coexist,” it said.

Jefferies, the investment bank, expects NFTs to reach $25 billion in value in the “very near term.” The global market for physical collectibles is pegged at $370 billion.

Some investors in digital assets have developed novel ideas on risk. “If you talk to people in the crypto space, and you tell them that you’re 100% invested in Bitcoin, they think that you’re super-risk-averse,” observes SoFi’s Young. “It’s like the boomer coin.”

That isn’t far off from what we heard from Ranae Arnette, 33, who was in Times Square this past week to promote a prelaunch NFT marketplace called Snow Crash. Her personal portfolio consists of stock options for “daily plays” and cryptocurrency for long-term investment, but only a little Bitcoin. “It’s not going to give you the same return as if I were to invest in Shiba, which is like five decimals less than a penny,” she says.

Arnette was down $1,500 for the day, but had made $5,600 the day before, “so it doesn’t even feel like a loss,” she says. She learned about investing from podcasts and YouTube videos while stuck at home in the early days of the pandemic.

“I remember the first time that I opened my Robinhood app and I had made my paycheck in a day—in the first, like, 10 minutes of the stock market,” she says. “And I kind of just remember sitting at my desk at home with my computer in front of me, like, should I quit?” She went on to teach her mother, sister, brother, and friends to trade.

There is a temptation among seasoned investors to moralize about risk-taking in meme assets, and to expect a comeuppance at any moment for those who trade them. But another view is simply that digital natives have developed a way to monetize their ability to spot chat-room trends faster than the rest of us. It might be weird finance, but the same could be said of endless national budget deficits, years of negative real interest rates, and six-figure college degrees that lead to low-paying jobs.

And there is surely a path from meme-flipping to long-term savings.

This reporter, when in his early 20s, made a tidy little profit in a four-cent stock of such low quality that when it soared past $1, then died, one major newspaper called it “Nasdaq’s Billion Dollar Absurdity.” He didn’t turn to off-track betting or slots next. He backpacked through cheap countries until his winnings ran out, and has spent the decades since as a boring but content plunker of regular savings into the broad stock and bond markets.

And today, any promised comeuppance might take a while. J.P. Morgan’s Kelly expects only a gradual rise in interest rates, beginning late next year, with perhaps years more of silly asset pricing. Frontline Compliance’s Lynch says that new regulations could dampen some of the excitement in crypto and bring down prices, but also that rule makers are “not going to move fast enough, I guarantee you that.”

What to do? Buy something preposterous, by all means. A bubble like this is not to be missed. But spend entertainment funds, not investment capital. And while tastes vary, consider not using terms like “correlation” to justify the purchase. Wall Street has always been prone to physics envy and over-mathematization, but in truth, it has only a rough idea of how stocks behave, and those are four centuries old. Let’s all agree to skip the regression analysis on five-year-old cryptocoins.

Don’t confuse a quick success with a strategy. When it came to momentum trading, even the author of the laws of physical momentum was no Newton, shall we say. Sir Isaac sold his South Sea holdings for a profit, and then jumped back in and took a bath. And don’t imagine that everyone else is getting rich from meme assets. Winners blab, and losers clam up, skewing perception.

Crypto dabblers should track tips on Twitter and the WallStreetBets forum on Reddit—buzz is everything for such assets. Crypto skeptics should brace for the angry mob when sharing their views. That is standard bubble stuff. For those who can’t decide whether to stick a toe in, there are always crypto-adjacent stocks with plenty of risk, like Coinbase, an exchange platform, and publicly traded companies that set computer rigs to work in “mining” digital coins: Marathon Digital Holdings (MARA), Riot Blockchain (RIOT), and Hut 8 Mining (HUT), to name a few.

Above all, keep return expectations low—both for crypto flings and for nest eggs invested in more mundane assets. BofA Securities estimates that the S&P 500, not counting dividends, is now priced for 0.5% annual price declines over the next decade. The 10-year Treasury yield is percentage points below the latest reading on inflation.

One place to search for good deals is within cyclical stock sectors. They can boom and fizzle, but tend to perform in line with the market over time, and now they are cheaper compared with the market than they have been 91% of the time since 1945, according to James Paulsen, chief investment strategist at The Leuthold Group. Think materials, industrials, financials, and consumer-discretionary stocks and exchange-traded funds.

BofA says reinvested dividends could make the difference between positive and negative returns over the next decade. Goldman Sachs expects S&P 500 payments to rise by 5% a year over that stretch. Boring? Consider: Regular cash payments to shareholders were the breakthrough that centuries ago allowed joint venture companies to begin operating in perpetuity, instead of dissolving after each trip to split the profits. Dividends gave rise to stocks, not the other way around. They are at least as innovative as ape NFTs. Buy iShares Core Dividend Growth ETF (DGRO), yielding just over 2%, and tell your friends you’re a fintech investor.

Resist financial nihilism. We suspect that stocks and even bonds will compare well with Shiba Inu long term, and we are confident they will outdo Squid Game crypto this quarter. But this era of easy gains in nearly everything is probably close to winding down.

Barrons : Gene Therapy Is a Huge Opportunity. It Pays to be Patient.

Gene Therapy Is a Huge Opportunity. It Pays to be Patient.

America’s first injected gene therapy, Roche Holding ’s Luxturna, treated an eye disease inherited by a couple of thousand people. The next gene therapy to be approved, Novartis’ Zolgensma, helped 20,000 people born with a serious muscle disorder.

Now, genetic medicine developers are looking beyond rare diseases and aiming at more common afflictions. Diabetes. Heart disease. Wrinkles.

By changing the genetic instructions within cells, a one-time infusion could repair a heart attack’s damage, free someone from insulin shots, or lower cholesterol for a lifetime. With millions of potential patients, the consequences for the drug industry and healthcare system are far-reaching. True, these therapies may take a decade or more to reach the market, and their prices will have to come down far below Zolgensma’s $2.1 million per patient. Clinical trials could begin as early as next year.

Biotechs targeting not-so-rare diseases with genetic treatments include Regenxbio (ticker: RGNX), partnered with AbbVie (ABBV), and newer companies like Verve Therapeutics (VERV), Tenaya Therapeutics (TNYA), Krystal Biotech (KRYS), and a number of other start-ups. With exchange-traded funds such as ARK Genomic Revolution (ARKG) down 31% versus the S&P 500 index’s 17% gain since February, gene therapy plays have fallen to levels where investors might be willing to look ahead a decade or so when these one-time fixes may be common.

“These are real companies with real technologies,” says Eli Casdin, whose Casdin Capital has large stakes in cardiovascular treatment developers Verve and Tenaya. “The industry always starts where the clinical need is most acute but perhaps narrow, and then broadens its reach to things that are more prevalent, if less acute.”

Regenxbio has been at the center of gene-transfer therapy since 2009, when it licensed University of Pennsylvania techniques that turn hollowed-out viruses, called AAVs, into shuttles to carry genetic instructions into cells. Re-engineered AAVs became the platform for most of the industry, with Regenx supplying gene therapy developers like Novartis (NVS) and Ultragenyx Pharmaceutical (RARE).

Improving Vision
Some five years ago, Regenx began testing its own treatments. Furthest along is a gene therapy for a severe form of macular degeneration, an age-related disease of the retina that afflicts over two million people in developed countries, with about 200,000 new diagnoses each year in the U.S. It’s treated today with repeated injections of antibody drugs like Lucentis from Roche (RHHBY) and Novartis, and Eylea from Regeneron Pharmaceuticals (REGN). Regenx’s one-time treatment inserts a gene to produce the antibody in the eye. Early-phase clinical trials showed improved vision and reduced need for further antibody drugs. Researchers will share interim data in mid-November. A pivotal Phase 3 trial is under way and should conclude in a year or so.

A larger potential market awaits another gene therapy that Regenx is testing for diabetic retinopathy, the leading cause of blindness in working-age people that afflicts some eight million Americans. Early-trial patients showed vision improvements, and a Phase 2 study is under way.

Studies must validate Regenxbio’s retinal treatments. Rival Adverum Biotechnologies (ADVM) stopped testing a gene therapy this summer for a diabetic eye disease, after encountering safety problems. But in September, AbbVie said it would partner with Regenx on retinal gene therapies, with an upfront payment of $370 million and potential milestone payments of $1.4 billion. At $38 a share, and a $1.6 billion market cap, Regenx stock is worth half the value it had in 2018 amid the enthusiasm over Novartis’ $8.7 billion purchase of AveXis. The $900 million on Regenx’s balance sheet, and milestone payments, should sustain the yet-unprofitable biotech firm into the latter part of the decade, when bullish analysts like Raymond James’ Dane Leone project that sales could put Regenx in the black.

Treating Diabetes
Diabetes is growing worldwide. About 1.6 million Americans live with Type 1 diabetes, in which the immune system destroys the pancreas’ insulin-producing beta cells. Glucose monitoring and daily insulin shots can reduce the damage, but a number of start-ups are working on genetic therapies they hope will provide one-time repairs—perhaps also for the even more prevalent Type 2 diabetes.

University of Wisconsin transplant surgeon Hans Sollinger recruited veterans from AveXis to help his company, Endsulin, develop a gene therapy that one of its patents claims can start well-regulated insulin production in liver cells.

A second firm, Jaguar Gene Therapy, has backing from AveXis founders, Eli Lilly (LLY), and healthcare investors at Deerfield Management, to pursue treatments for diabetes and other metabolic diseases, with a gene-transfer technology that has been able to change alpha cells in a lab animal’s pancreas into insulin-producing beta cells. Jaguar’s research head Suku Nagendran says the firm is selecting AAV containers for its therapies and planning for manufacturing.

Gene therapies for a common disease like diabetes will require manufacturing scale that the genetics industry has not yet seen, says Kriya Therapeutics’ CEO Shankar Ramaswamy. At the company’s facility in Research Triangle Park, N.C., Kriya hopes that its high-efficiency processes will reduce costs by an order of magnitude as it commercializes a diabetes gene therapy pioneered at the Autonomous University of Barcelona, Spain, where the approach freed diabetic dogs from the need for insulin shots for up to eight years. Applications to begin human trials could be filed next year, he says.

Genetic Medicine for the Masses
Gene therapies started by treating rare diseases. Now, companies want to bring the once-and-done treatments to widespread ills.
“Gene therapy is where monoclonal antibodies were, decades ago,” says Ramaswamy. “We need solutions that bring down costs enough to help immense numbers of people.”

Each of these diabetes gene therapy programs is trying a different approach, notes Gbola Amusa, the chief scientific officer at investment bank Chardan Capital Markets. He figures that improves the odds of one succeeding.

Fixing Hearts
As widespread as diabetes is, heart disease is larger, diagnosed in 30 million Americans. It’s the world’s No. 1 killer, and heart attacks cause more deaths than all cancers combined.

Tenaya Therapeutics was launched five years ago with this in mind, says CEO Faraz Ali, but it decided to get there gradually by first bringing out therapies for genetic conditions that lead to heart failure. After good results in animals, Tenaya will seek permission to start human trials next year for therapies aimed at conditions that affect more than 200,000 Americans. Cowen analyst Ritu Baral predicts that each of the three therapies could become a multibillion-dollar market in a decade.

By 2023, Tenaya could be ready for clinical trials of gene therapies that regenerate heart muscle damaged in the 800,000 heart attacks suffered by Americans each year. One Tenaya technique reprograms the heart’s connective tissue cells into becoming muscle cells. Another prompts heart muscle cells to divide, which they normally don’t do after birth. Last year, Tenaya researchers demonstrated heart-cell reprogramming for the first time in a large animal, by repairing heart-attack damage in a pig.

Tenaya is planning its heart-therapy production with large volumes in mind. Regulators have halted clinical trials of other gene therapy developers when companies changed their manufacturing processes in midstream. “Modest changes in manufacturing can make dramatic changes in your gene therapy product,” says Ali. “You can’t wait until you’re in Phase 3 and say, ‘Wow, we’ve got great data...we should think about manufacturing.’”

Gene therapy for the masses will require manufacturers to scale reaction vessels, where microorganisms produce biologic drugs, from a thousand liters to 10,000 liters or more. Without reducing the cost of goods, says Ali, the industry won’t be able to supply large markets at commercially—and societally—viable prices.

After a July initial offering at $15 a share, Tenaya has about $300 million in cash, which it believes will sustain it into 2023. The current $25 stock price values the venture at $1 billion.

Verve Therapeutics is eyeing an even bigger market, with a once-and-done therapy to lower the risk of cardiovascular disease. Statin pills can do this, of course, when taken daily for decades. New and expensive injections of drugs like Repatha from Amgen (AMGN) or Praluent from Regeneron also dramatically cut cholesterol by inhibiting an enzyme called PCSK9.

Using a new gene-editing technology called base-editing, licensed from Beam Therapeutics (BEAM), Verve knocks out the gene that drives PCSK9 production. A single infusion has cut cholesterol levels in monkeys by 60% for 15 months and counting. The company hopes to begin human trials next year, starting in families that suffer from overactivity in that gene. Verve also has sights on another gene that causes high levels of cholesterol and triglycerides. After initially targeting several million people who have inherited particularly bad versions of these genes, Verve ultimately wants to treat the masses. “These genes are just bad actors,” says Verve CEO Sekar Kathiresan. “You can get rid of them and just get healthier.”

A June initial offering at $19 a share raised $300 million and leaves Verve with cash it expects to suffice until 2024. Even with Verve stock now at $55, Guggenheim Securities analysts see more than 50% upside.

The clinical trials of genetic therapies against rare, severe diseases have taken longer than some investors expected. Large, long-term studies will probably be required for genetic treatments targeting everyday diseases like atherosclerosis, says Matt Feinstein, a cardiology professor at Northwestern University. “A really rare side effect that only affects one-in-50,000 people might not show up in a clinical trial,” he says. “But if the therapy gets out to millions of people, you might start seeing the side effect.”

That said, Feinstein believes that a safe, one-time treatment that lowers blood lipids for a lifetime is well worth pursuing.

Smoothing Wrinkles
Krystal Biotech is another company that could have a gene therapy for a large market. Krystal expects data by year end in a Phase 3 study of its treatment for a serious skin disorder caused by defects in the gene that produces collagen. Early studies showed that Krystal could remedy the disease with genes delivered in re-engineered versions of the HSV-1 virus. Unlike gene therapy vehicles like the AAV virus, HSV-1 doesn’t trigger an immune reaction, so it can be redosed when new skin cells need a repeat.

That feature led Krystal to announce a new venture in March called Jeune, which will test aesthetic applications of its collagen therapy. Age-related wrinkles, for example, result from a reduction in collagen output. Excitement over this Botox-size market sent Krystal shares above $80 this year, before they settled back to a recent $53.

Krystal declined to discuss its collagen therapies. But fans like H.C. Wainwright’s Joseph Pantginis think the shares could double.

Meanwhile, both companies and payers will have to figure out how to price a once-and-done gene therapy for the masses, once it’s approved. But it has been done before, for transplants and heart bypasses. “Perfecting the science and manufacturing are just entry stakes,” says Tenaya CEO Ali. “We have to create something that is sustainable, that the healthcare system can afford.”